TGFB1 and pulmonary fibrosis: Hence, blockade of TGF‐β activation by integrins is an attractive therapeutic target in pulmonary fibrosis and COPD, as well as during pulmonary infections, with the potential to block context‐specific TGF‐β function in disease without compromising the tissue‐protective effects of the cytokine.